betaine has been researched along with Atherosclerosis in 23 studies
glycine betaine : The amino acid betaine derived from glycine.
Atherosclerosis: A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.
Excerpt | Relevance | Reference |
---|---|---|
"BET supplementation may be effective in preventing hyperlipidemia, disturbed NO availability, oxidative stress, and the development of fatty liver and atherosclerotic lesions that might result from excess amounts of cholesterol and methionine in the diet." | 7.88 | Effects of betaine supplementation on nitric oxide metabolism, atherosclerotic parameters, and fatty liver in guinea pigs fed a high cholesterol plus methionine diet. ( Bekpınar, S; Çevik, A; Genc, S; Gürdöl, F; Küskü-Kiraz, Z; Olgaç, V; Ünlücerci, Y; Uysal, M, 2018) |
"The elevation of the levels of l-carnitine and its fatty acid esters, acylcarnitines, in tissue or plasma has been linked to the development of atherosclerosis." | 7.81 | Methyl-γ-butyrobetaine decreases levels of acylcarnitines and attenuates the development of atherosclerosis. ( Cirule, H; Dambrova, M; Grinberga, S; Kuka, J; Liepinsh, E; Makarova, E; Makrecka-Kuka, M; Sevostjanovs, E; Vilskersts, R; Volska, K, 2015) |
"Low dietary intake of the essential nutrient choline and its metabolite betaine may increase atherogenesis both through effects on homocysteine methylation pathways as well as through choline's antioxidants properties." | 7.74 | Usual choline and betaine dietary intake and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. ( Bidulescu, A; Chambless, LE; Heiss, G; Siega-Riz, AM; Zeisel, SH, 2007) |
"l-Carnitine, an abundant nutrient in red meat, accelerates atherosclerosis in mice via gut microbiota-dependent formation of trimethylamine (TMA) and trimethylamine N-oxide (TMAO) via a multistep pathway involving an atherogenic intermediate, γ-butyrobetaine (γBB)." | 5.30 | l-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans. ( Bartlett, D; Cody, DB; Copeland, MF; Culley, MK; Dai, HJ; DiDonato, JA; Fu, X; Garcia-Garcia, JC; Gu, X; Hazen, SL; Kirsop, J; Koeth, RA; Lam-Galvez, BR; Levison, BS; Li, L; Li, XS; Tang, WHW; Wang, Z; Wu, Y, 2019) |
"BET supplementation may be effective in preventing hyperlipidemia, disturbed NO availability, oxidative stress, and the development of fatty liver and atherosclerotic lesions that might result from excess amounts of cholesterol and methionine in the diet." | 3.88 | Effects of betaine supplementation on nitric oxide metabolism, atherosclerotic parameters, and fatty liver in guinea pigs fed a high cholesterol plus methionine diet. ( Bekpınar, S; Çevik, A; Genc, S; Gürdöl, F; Küskü-Kiraz, Z; Olgaç, V; Ünlücerci, Y; Uysal, M, 2018) |
"The elevation of the levels of l-carnitine and its fatty acid esters, acylcarnitines, in tissue or plasma has been linked to the development of atherosclerosis." | 3.81 | Methyl-γ-butyrobetaine decreases levels of acylcarnitines and attenuates the development of atherosclerosis. ( Cirule, H; Dambrova, M; Grinberga, S; Kuka, J; Liepinsh, E; Makarova, E; Makrecka-Kuka, M; Sevostjanovs, E; Vilskersts, R; Volska, K, 2015) |
"L-carnitine, a nutrient in red meat, was recently reported to accelerate atherosclerosis via a metaorganismal pathway involving gut microbial trimethylamine (TMA) formation and host hepatic conversion into trimethylamine-N-oxide (TMAO)." | 3.80 | γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. ( Buffa, JA; Culley, MK; DiDonato, JA; Gregory, JC; Hazen, SL; Koeth, RA; Levison, BS; Li, L; Lusis, AJ; Org, E; Smith, JD; Tang, WHW; Wang, Z; Wu, Y, 2014) |
"Long-term mildronate treatment decreases L-carnitine content in aortic tissues and attenuates the development of atherosclerosis in apoE/LDLR(-/-) mice." | 3.75 | Mildronate, a regulator of energy metabolism, reduces atherosclerosis in apoE/LDLR-/- mice. ( Chlopicki, S; Dambrova, M; Grinberga, S; Kalvinsh, I; Liepinsh, E; Mateuszuk, L; Vilskersts, R, 2009) |
"Betaine could inhibit the development of atherosclerosis via anti-inflammation." | 3.74 | [Anti-atherosclerotic effect of betaine in apolipoprotein E-deficient mice]. ( DU, YP; Fan, RX; Hou, MJ; Lü, SW; Zhu, HL, 2008) |
"Low dietary intake of the essential nutrient choline and its metabolite betaine may increase atherogenesis both through effects on homocysteine methylation pathways as well as through choline's antioxidants properties." | 3.74 | Usual choline and betaine dietary intake and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. ( Bidulescu, A; Chambless, LE; Heiss, G; Siega-Riz, AM; Zeisel, SH, 2007) |
"Atherosclerosis is a hallmark of cardiovascular disease, and lifestyle strongly impacts its onset and progression." | 1.72 | TMAO Upregulates Members of the miR-17/92 Cluster and Impacts Targets Associated with Atherosclerosis. ( Blanco, R; Daimiel, L; Dávalos, A; Díez-Ricote, L; Micó, V; Ordovás, JM; Ruiz-Valderrey, P; Tomé-Carneiro, J, 2022) |
"Betaine serves as a methyl donor in a reaction converting homocysteine to methionine." | 1.35 | Betaine supplementation attenuates atherosclerotic lesion in apolipoprotein E-deficient mice. ( Du, Y; Fan, R; Hou, M; Ling, W; Lv, S; Tang, Z; Zhu, H, 2009) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (8.70) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (26.09) | 29.6817 |
2010's | 11 (47.83) | 24.3611 |
2020's | 4 (17.39) | 2.80 |
Authors | Studies |
---|---|
Xiong, X | 1 |
Zhou, J | 1 |
Fu, Q | 1 |
Xu, X | 1 |
Wei, S | 1 |
Yang, S | 1 |
Chen, B | 1 |
Díez-Ricote, L | 1 |
Ruiz-Valderrey, P | 1 |
Micó, V | 1 |
Blanco, R | 1 |
Tomé-Carneiro, J | 1 |
Dávalos, A | 1 |
Ordovás, JM | 1 |
Daimiel, L | 1 |
Blachier, F | 1 |
Andriamihaja, M | 1 |
Blais, A | 1 |
Zheng, Y | 1 |
He, JQ | 1 |
Küskü-Kiraz, Z | 1 |
Genc, S | 1 |
Bekpınar, S | 1 |
Ünlücerci, Y | 1 |
Çevik, A | 1 |
Olgaç, V | 1 |
Gürdöl, F | 1 |
Uysal, M | 1 |
Koeth, RA | 2 |
Lam-Galvez, BR | 1 |
Kirsop, J | 1 |
Wang, Z | 3 |
Levison, BS | 3 |
Gu, X | 1 |
Copeland, MF | 1 |
Bartlett, D | 1 |
Cody, DB | 1 |
Dai, HJ | 1 |
Culley, MK | 2 |
Li, XS | 1 |
Fu, X | 2 |
Wu, Y | 3 |
Li, L | 2 |
DiDonato, JA | 3 |
Tang, WHW | 2 |
Garcia-Garcia, JC | 1 |
Hazen, SL | 3 |
Sinha, A | 1 |
Ma, Y | 1 |
Scherzer, R | 1 |
Rahalkar, S | 1 |
Neilan, BD | 1 |
Crane, H | 1 |
Drozd, D | 1 |
Martin, J | 1 |
Deeks, SG | 1 |
Hunt, P | 1 |
Hsue, PY | 1 |
Claus, SP | 1 |
Buffa, JA | 1 |
Gregory, JC | 1 |
Org, E | 1 |
Smith, JD | 2 |
Lusis, AJ | 2 |
Drosos, I | 1 |
Tavridou, A | 1 |
Kolios, G | 1 |
Vilskersts, R | 2 |
Kuka, J | 1 |
Liepinsh, E | 2 |
Makrecka-Kuka, M | 1 |
Volska, K | 1 |
Makarova, E | 1 |
Sevostjanovs, E | 1 |
Cirule, H | 1 |
Grinberga, S | 2 |
Dambrova, M | 2 |
Berge, RK | 2 |
Ramsvik, MS | 1 |
Bohov, P | 1 |
Svardal, A | 2 |
Nordrehaug, JE | 1 |
Rostrup, E | 1 |
Bruheim, I | 1 |
Bjørndal, B | 1 |
Trøseid, M | 1 |
Hov, JR | 1 |
Nestvold, TK | 1 |
Thoresen, H | 1 |
Lappegård, KT | 1 |
Fan, RX | 1 |
Lü, SW | 1 |
DU, YP | 1 |
Hou, MJ | 1 |
Zhu, HL | 1 |
Lv, S | 1 |
Fan, R | 1 |
Du, Y | 1 |
Hou, M | 1 |
Tang, Z | 1 |
Ling, W | 1 |
Zhu, H | 1 |
Mateuszuk, L | 1 |
Kalvinsh, I | 1 |
Chlopicki, S | 1 |
Manicke, NE | 1 |
Nefliu, M | 1 |
Wu, C | 1 |
Woods, JW | 1 |
Reiser, V | 1 |
Hendrickson, RC | 1 |
Cooks, RG | 1 |
Rak, K | 1 |
Rader, DJ | 1 |
Klipfell, E | 1 |
Bennett, BJ | 1 |
Koeth, R | 1 |
Dugar, B | 1 |
Feldstein, AE | 1 |
Britt, EB | 1 |
Chung, YM | 1 |
Schauer, P | 1 |
Allayee, H | 1 |
Tang, WH | 1 |
MORRISON, LM | 1 |
FAZIO, B | 1 |
BALESTRERI, R | 1 |
Colgan, SM | 1 |
Austin, RC | 1 |
Bidulescu, A | 1 |
Chambless, LE | 1 |
Siega-Riz, AM | 1 |
Zeisel, SH | 1 |
Heiss, G | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease[NCT01731236] | Early Phase 1 | 100 participants (Anticipated) | Interventional | 2011-02-11 | Enrolling by invitation | ||
"Plant-Based Meat vs Animal Red Meat: a Randomized Cross-over Trial"[NCT04510324] | 41 participants (Actual) | Interventional | 2020-11-01 | Completed | |||
Low Fat Vegan Diet or American Heart Association Diet, Impact on Biomarkers of Inflammation, Oxidative Stress and Cardiovascular Risk in Obese 9-18 y.o. With Elevated Cholesterol: A Four Week Randomized Trial[NCT01817491] | 60 participants (Actual) | Interventional | 2013-03-31 | Completed | |||
Effect of Choline Source and Gut Microbiota Composition on Trimethylamine-N-oxide Response in Humans[NCT04255368] | 44 participants (Actual) | Interventional | 2017-11-09 | Completed | |||
Effects of Choline Supplementation on Fetal Growth in Gestational Diabetes Mellitus[NCT04302168] | 60 participants (Anticipated) | Interventional | 2020-04-01 | Recruiting | |||
Impact of Diet and Gut Microbiota on Trimethylamine-N-oxide Production and Fate in Humans[NCT02558673] | 40 participants (Actual) | Interventional | 2014-05-31 | Completed | |||
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)[NCT02016430] | 150 participants (Anticipated) | Interventional | 2014-04-04 | Recruiting | |||
Analysis of MicroBial Metabolites After Eating Refined Food[NCT04308473] | 46 participants (Actual) | Interventional | 2020-09-01 | Active, not recruiting | |||
Effects of Choline From Eggs vs. Supplements on the Generation of TMAO in Humans (EGGS)[NCT03039023] | 86 participants (Actual) | Interventional | 2016-09-02 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
PAQ self reported questions based on activity level from 1 (low activity) to 5 (high activity), overall PAQ score is a mean of the questions. (NCT01817491)
Timeframe: baseline, 4 weeks
Intervention | units on a scale (Mean) |
---|---|
Reduced Fat Vegan Diet | 0.22 |
American Heart Association Diet | -0.16 |
Body mass index z-scores, also called BMI standard deviation (s.d.) scores, are measures of relative weight adjusted for child age and sex. Given a child's age, sex, BMI, and an appropriate reference standard, a BMI z-score (or its equivalent BMI-for-age percentile) can be determined. Negative BMI z-scores indicate a BMI that is lower than the population mean, while positive BMI scores indicate a value that is higher than the population mean. A decrease in the BMI z-score over time indicate a lowering of the BMI. Z-scores of 1.03 and 1.64 correspond to the 85th and 95th percentiles of BMI-for-age, which are the definitions of overweight and obesity in children. (NCT01817491)
Timeframe: baseline, 4 weeks
Intervention | Z Score (Mean) |
---|---|
Reduced Fat Vegan Diet | -0.14 |
American Heart Association Diet | -0.03 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
Intervention | Z score (Mean) |
---|---|
PB/AHA | -0.13 |
PAQ self reported questions based on activity level from 1 (low activity) to 5 (high activity), overall PAQ score is a mean of the questions. (NCT01817491)
Timeframe: Baseline, 4 weeks
Intervention | units on a scale (Mean) |
---|---|
PB/AHA | 0.39 |
(NCT01817491)
Timeframe: baseline, 4 weeks
Intervention | mm Hg (Mean) | |||
---|---|---|---|---|
Children Systolic BP | Parents Systolic BP | Children Diastolic BP | Parent Diastolic BP | |
American Heart Association Diet | -5.14 | -3.14 | -4.36 | -6.64 |
Reduced Fat Vegan Diet | -6.43 | -7.96 | -2.61 | -3.46 |
(NCT01817491)
Timeframe: baseline, 4 weeks
Intervention | BMI percentile (Mean) | |
---|---|---|
Children | Parents | |
American Heart Association Diet | -0.08 | -0.73 |
Reduced Fat Vegan Diet | -1.12 | -1.29 |
(NCT01817491)
Timeframe: baseline, 4 weeks
Intervention | cm (Mean) | |||
---|---|---|---|---|
Children Waist Circumference | Parents Waist Circumference | Children Midarm Circumference | Parents Midarm Circumference | |
American Heart Association Diet | -2.96 | -0.49 | -1.14 | 0.35 |
Reduced Fat Vegan Diet | -1.53 | -1.94 | -2.02 | -1.32 |
(NCT01817491)
Timeframe: baseline, 4 weeks
Intervention | mg/dL (Mean) | |
---|---|---|
Children | Parent | |
American Heart Association Diet | -.64 | -5.43 |
Reduced Fat Vegan Diet | 0.93 | 4.93 |
(NCT01817491)
Timeframe: baseline, 4 weeks
Intervention | percentage (Mean) | |
---|---|---|
Children | Parent | |
American Heart Association Diet | 0.21 | 0.14 |
Reduced Fat Vegan Diet | 0.17 | -0.16 |
(NCT01817491)
Timeframe: baseline, 4 weeks
Intervention | mg/L (Mean) | |
---|---|---|
Children | Parent | |
American Heart Association Diet | 2.78 | 0.21 |
Reduced Fat Vegan Diet | -2.09 | -0.24 |
(NCT01817491)
Timeframe: baseline, 4 weeks
Intervention | pg/ml (Mean) | |
---|---|---|
Children | Parent | |
American Heart Association Diet | -0.19 | -0.19 |
Reduced Fat Vegan Diet | -0.17 | 0.16 |
(NCT01817491)
Timeframe: baseline, 4 weeks
Intervention | uU/ml (Mean) | |
---|---|---|
Children | Parents | |
American Heart Association Diet | 3.16 | -3.15 |
Reduced Fat Vegan Diet | -5.42 | -3.11 |
(NCT01817491)
Timeframe: baseline, 4 weeks
Intervention | mg/dL (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
total cholesterol children | triglycerides children | high-density lipoprotein cholesterol children | low-density lipoprotein cholesterol children | total cholesterol parents | triglycerides parents | high-density lipoprotein cholesterol parents | low-density lipoprotein cholesterol parents | |
American Heart Association Diet | -16.50 | -13.14 | -2.93 | -11.00 | -7.14 | 16.86 | 16.86 | -5.50 |
Reduced Fat Vegan Diet | -22.50 | -25.50 | -5.93 | -13.14 | -33.79 | 6.21 | -8.14 | -27.00 |
(NCT01817491)
Timeframe: baseline, 4 weeks
Intervention | U/L (Mean) | |||
---|---|---|---|---|
alanine aminotransferase (ALT) children | aspartate aminotransferase (AST) children | alanine aminotransferase (ALT) parents | aspartate aminotransferase (AST) parents | |
American Heart Association Diet | -1.14 | 0.00 | 4.57 | 4.43 |
Reduced Fat Vegan Diet | 0.79 | 2.79 | 0.86 | 0.14 |
(NCT01817491)
Timeframe: baseline, 4 weeks
Intervention | pmol/L (Mean) | |
---|---|---|
Children | Parent | |
American Heart Association Diet | -69.23 | 1.78 |
Reduced Fat Vegan Diet | -75.34 | 16.91 |
(NCT01817491)
Timeframe: baseline, 4 weeks
Intervention | kg (Mean) | |
---|---|---|
Children | Parents | |
American Heart Association Diet | -1.55 | -2.01 |
Reduced Fat Vegan Diet | -3.05 | -3.64 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
Intervention | ratio (Mean) | |||
---|---|---|---|---|
Children adj mean ratio systolic BP | Children adj mean ratio diastolic BP | parents adj mean ratio systolic BP | parents adj mean ratio diastolic BP | |
PB/AHA | 1.87 | 1.01 | 0.97 | 1.03 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
Intervention | percentile (Mean) | |
---|---|---|
Children Change in BMI | Parents Change in BMI | |
PB/AHA | -1.17 | -0.69 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
Intervention | cm (Mean) | |||
---|---|---|---|---|
children waist circumference | parents waist circumference | children arm circumference | parents arm circumference | |
PB/AHA | 1.32 | -1.14 | -1.25 | -1.68 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
Intervention | kg (Mean) | |
---|---|---|
Children Weight | Parents Weight | |
PB/AHA | -1.71 | -1.95 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
Intervention | mg/dL (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
CHOL children | TRIG children | HDL children | LDL children | CHOL parents | TRIG parents | HDL parents | LDL parents | |
PB/AHA | -10.34 | 1.01 | 0.17 | 0.95 | -27.29 | 0.95 | 0.94 | -21.92 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
Intervention | ratio (Mean) | |
---|---|---|
Children | Parents | |
PB/AHA | 1.01 | 1.06 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
Intervention | ratio (Mean) | |
---|---|---|
Children | Parents | |
PB/AHA | 0.99 | 0.96 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
Intervention | ratio (Mean) | |
---|---|---|
Children | Parents | |
PB/AHA | 0.46 | 0.68 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
Intervention | ratio (Mean) | |
---|---|---|
Children | Parents | |
PB/AHA | 0.26 | 1.14 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
Intervention | ratio (Mean) | |
---|---|---|
Children | Parents | |
PB/AHA | 0.7 | 0.87 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
Intervention | ratio (Mean) | |||
---|---|---|---|---|
ALT children | AST children | ALT parents | AST parents | |
PB/AHA | 1 | 1.13 | 0.85 | 0.83 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
Intervention | ratio (Mean) | |
---|---|---|
Children | Parents | |
PB/AHA | 0.95 | 0.93 |
Changes in levels of non-labeled TMAO from baseline to Day 28 measured by established mass spectrometry techniques. (NCT03039023)
Timeframe: Baseline, Day 28
Intervention | mg in 24 hours (Median) | |
---|---|---|
Baseline | Day 28 | |
Choline Bitartrate Tablets | 26.2 | 139.0 |
Egg Whites + Choline Bitartrate Tablets | 29.3 | 186.9 |
Hardboiled Eggs + Choline Bitartrate Tablets | 27.5 | 221.8 |
Phosphatidylcholine Capsules | 15.8 | 33.1 |
Whole Hardboiled Eggs | 24.3 | 28.5 |
Changes in measured HDL levels between baseline and Day 28 (NCT03039023)
Timeframe: Baseline, Day 28
Intervention | mg/dL (Median) | |
---|---|---|
Baseline | Day 28 | |
Choline Bitartrate Tablets | 49 | 51 |
Egg Whites + Choline Bitartrate Tablets | 48 | 50 |
Hardboiled Eggs + Choline Bitartrate Tablets | 57 | 56 |
Phosphatidylcholine Capsules | 61 | 62 |
Whole Hardboiled Eggs | 48 | 49 |
Changes in measured LDL levels between baseline and Day 28 (NCT03039023)
Timeframe: Baseline, Day 28
Intervention | mg/dL (Median) | |
---|---|---|
Baseline | Day 28 | |
Choline Bitartrate Tablets | 90 | 94 |
Egg Whites + Choline Bitartrate Tablets | 104 | 101 |
Hardboiled Eggs + Choline Bitartrate Tablets | 108 | 118 |
Phosphatidylcholine Capsules | 107 | 106 |
Whole Hardboiled Eggs | 91 | 86 |
Changes in total cholesterol levels between baseline and Day 28 (NCT03039023)
Timeframe: Baseline, Day 28
Intervention | mg/dL (Median) | |
---|---|---|
Baseline | Day 28 | |
Choline Bitartrate Tablets | 180 | 172 |
Egg Whites + Choline Bitartrate Tablets | 186 | 178 |
Hardboiled Eggs + Choline Bitartrate Tablets | 187 | 198 |
Phosphatidylcholine Capsules | 175 | 172 |
Whole Hardboiled Eggs | 156 | 158 |
Changes in measured triglyceride levels between baseline and Day 28 (NCT03039023)
Timeframe: Baseline, Day 28
Intervention | mg/dL (Median) | |
---|---|---|
Baseline | Day 28 | |
Choline Bitartrate Tablets | 106 | 96 |
Egg Whites + Choline Bitartrate Tablets | 122 | 109 |
Hardboiled Eggs + Choline Bitartrate Tablets | 103 | 97 |
Phosphatidylcholine Capsules | 74 | 84 |
Whole Hardboiled Eggs | 86 | 100 |
Fasting plasma levels of betaine from samples obtained at baseline and at day 28 were compared. (NCT03039023)
Timeframe: Baseline, Day 28
Intervention | uM (Median) | |
---|---|---|
Baseline | Day 28 | |
Choline Bitartrate Tablets | 38.2 | 69.0 |
Egg Whites + Choline Bitartrate Tablets | 38.7 | 59.8 |
Hardboiled Eggs + Choline Bitartrate Tablets | 30.7 | 46.9 |
Phosphatidylcholine Capsules | 33.6 | 46.3 |
Whole Hardboiled Eggs | 28.1 | 39.7 |
Fasting plasma levels of carnitine from samples obtained at baseline and at day 28 were compared. (NCT03039023)
Timeframe: Baseline, Day 28
Intervention | uM (Median) | |
---|---|---|
Baseline | Day 28 | |
Choline Bitartrate Tablets | 21.2 | 18.7 |
Egg Whites + Choline Bitartrate Tablets | 21.1 | 18.9 |
Hardboiled Eggs + Choline Bitartrate Tablets | 21.5 | 15.6 |
Phosphatidylcholine Capsules | 23.4 | 20.8 |
Whole Hardboiled Eggs | 19.1 | 19.4 |
Fasting plasma levels of choline from samples obtained at baseline and at day 28 were compared. (NCT03039023)
Timeframe: Baseline, Day 28
Intervention | uM (Median) | |
---|---|---|
Baseline | Day 28 | |
Choline Bitartrate Tablets | 7.5 | 12.9 |
Egg Whites + Choline Bitartrate Tablets | 9.5 | 12.8 |
Hardboiled Eggs + Choline Bitartrate Tablets | 8.5 | 14.0 |
Phosphatidylcholine Capsules | 7.6 | 10.6 |
Whole Hardboiled Eggs | 8.3 | 10.9 |
Changes in levels of non-labeled TMAO from baseline to end-of-study (day 28) as measured by established techniques by mass spectrometry. (NCT03039023)
Timeframe: Baseline, 28 days
Intervention | uM (Median) | |
---|---|---|
Baseline | Day 28 | |
Choline Bitartrate Tablets | 1.9 | 11.1 |
Egg Whites + Choline Bitartrate Tablets | 2.6 | 28.1 |
Hardboiled Eggs + Choline Bitartrate Tablets | 2.3 | 12.3 |
Phosphatidylcholine Capsules | 2.8 | 3.4 |
Whole Hardboiled Eggs | 2.0 | 2.3 |
The activation and functioning of platelets within a single subject will be compared before and after increased choline intake. (NCT03039023)
Timeframe: Baseline, Day 28
Intervention | aggregation percentage (Median) | |
---|---|---|
Baseline | Day 28 | |
Choline Bitartrate Tablets | 2.6 | 12.8 |
Egg Whites + Choline Bitartrate Tablets | 3.0 | 29.4 |
Hardboiled Eggs + Choline Bitartrate Tablets | 2.3 | 12.3 |
Phosphatidylcholine Capsules | 2.8 | 3.4 |
Whole Hardboiled Eggs | 2.6 | 3.6 |
2 reviews available for betaine and Atherosclerosis
Article | Year |
---|---|
Sulfur-Containing Amino Acids and Lipid Metabolism.
Topics: Amino Acids, Sulfur; Animals; Atherosclerosis; Betaine; Cholesterol; Cysteine; Dietary Proteins; Die | 2020 |
New aspects on the metabolic role of intestinal microbiota in the development of atherosclerosis.
Topics: Animals; Atherosclerosis; Betaine; Carnitine; Choline; Humans; Intestinal Mucosa; Intestines; Methyl | 2015 |
2 trials available for betaine and Atherosclerosis
Article | Year |
---|---|
l-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans.
Topics: Animals; Atherosclerosis; Betaine; Carnitine; Clostridiales; Female; Gastrointestinal Microbiome; Hu | 2019 |
l-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans.
Topics: Animals; Atherosclerosis; Betaine; Carnitine; Clostridiales; Female; Gastrointestinal Microbiome; Hu | 2019 |
l-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans.
Topics: Animals; Atherosclerosis; Betaine; Carnitine; Clostridiales; Female; Gastrointestinal Microbiome; Hu | 2019 |
l-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans.
Topics: Animals; Atherosclerosis; Betaine; Carnitine; Clostridiales; Female; Gastrointestinal Microbiome; Hu | 2019 |
Krill oil reduces plasma triacylglycerol level and improves related lipoprotein particle concentration, fatty acid composition and redox status in healthy young adults - a pilot study.
Topics: Adolescent; Adult; Animals; Atherosclerosis; Betaine; Carnitine; Choline; Chylomicrons; Cytokines; D | 2015 |
19 other studies available for betaine and Atherosclerosis
Article | Year |
---|---|
The associations between TMAO-related metabolites and blood lipids and the potential impact of rosuvastatin therapy.
Topics: Atherosclerosis; Betaine; Carnitine; Cholesterol, LDL; Choline; Humans; Lipids; Methylamines; Rosuva | 2022 |
TMAO Upregulates Members of the miR-17/92 Cluster and Impacts Targets Associated with Atherosclerosis.
Topics: Animals; Atherosclerosis; Betaine; Cardiovascular Diseases; Carnitine; Choline; Humans; Inflammation | 2022 |
Pathogenic Mechanisms of Trimethylamine N-Oxide-induced Atherosclerosis and Cardiomyopathy.
Topics: Animals; Atherosclerosis; Betaine; Cardiomyopathies; Cardiovascular Diseases; Humans; Methylamines | 2022 |
Effects of betaine supplementation on nitric oxide metabolism, atherosclerotic parameters, and fatty liver in guinea pigs fed a high cholesterol plus methionine diet.
Topics: Animals; Arginine; Atherosclerosis; Betaine; Cholesterol; Cholesterol, Dietary; Diet, High-Fat; Diet | 2018 |
Carnitine Is Associated With Atherosclerotic Risk and Myocardial Infarction in HIV -Infected Adults.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atherosclerosis; Betaine; Carnitine; Carotid Artery Di | 2019 |
Mammalian-microbial cometabolism of L-carnitine in the context of atherosclerosis.
Topics: Animals; Atherosclerosis; Betaine; Carnitine; Female; Gastrointestinal Tract; Methylamines | 2014 |
γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO.
Topics: Animals; Atherosclerosis; Betaine; Carnitine; Female; Gastrointestinal Tract; Methylamines; Mice; Mi | 2014 |
Methyl-γ-butyrobetaine decreases levels of acylcarnitines and attenuates the development of atherosclerosis.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Betaine; Carnitine; Disease Progression; Female; | 2015 |
Major Increase in Microbiota-Dependent Proatherogenic Metabolite TMAO One Year After Bariatric Surgery.
Topics: Adult; Atherosclerosis; Bariatric Surgery; Betaine; Body Mass Index; Cardiovascular Diseases; Carnit | 2016 |
[Anti-atherosclerotic effect of betaine in apolipoprotein E-deficient mice].
Topics: Animals; Apolipoproteins E; Atherosclerosis; Betaine; Chemokine CCL2; Dietary Supplements; Disease M | 2008 |
Betaine supplementation attenuates atherosclerotic lesion in apolipoprotein E-deficient mice.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Betaine; Chemokine CCL2; Dietary Supplements; Di | 2009 |
Mildronate, a regulator of energy metabolism, reduces atherosclerosis in apoE/LDLR-/- mice.
Topics: Animals; Aorta; Atherosclerosis; Betaine; Cardiovascular Agents; Carnitine; Energy Metabolism; Femal | 2009 |
Imaging of lipids in atheroma by desorption electrospray ionization mass spectrometry.
Topics: Atherosclerosis; Betaine; Cholesterol; Humans; Phosphatidylcholines; Phospholipids; Spectrometry, Ma | 2009 |
Cardiovascular disease: the diet-microbe morbid union.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Choline; Diet; Dietary Fats; | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Topics: Animals; Atherosclerosis; Betaine; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Choline; D | 2011 |
Results of betaine treatment of atherosclerosis.
Topics: Arteriosclerosis; Atherosclerosis; Betaine; Coronary Disease; Fabaceae; Glycine | 1952 |
[Treatment of human atherosclerosis with betaine].
Topics: Arteriosclerosis; Atherosclerosis; Betaine; Choline; Humans | 1961 |
Homocysteinylation of metallothionein impairs intracellular redox homeostasis: the enemy within!
Topics: Atherosclerosis; Betaine; Endothelium, Vascular; Folic Acid; Homeostasis; Homocysteine; Humans; Hype | 2007 |
Usual choline and betaine dietary intake and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study.
Topics: Atherosclerosis; Betaine; Choline; Coronary Disease; Diet; Female; Follow-Up Studies; Humans; Incide | 2007 |